La Toronja

Appendix 1: Grapefruit Interacting Drugs and Associated Oral Bioavailability, Adverse Event(s), Risk Ranking and
Potential Alternative Medications
Interacting Drugs

Innate Oral
Bioavailability*Dose-Related Drug
Adverse Event(s)

Predicted Interaction
Risk Rank **

intermediate
high
not known
intermediate
low
high
incomplete
intermediate
incomplete
intermediate
not knownnot known
not known

torsade de pointes, myelotoxicity
loss of efficacy
torsade de pointes, myelotoxicity
myelotoxicity
myelotoxicity, nephrotoxicity
myelotoxicity
torsade de pointes,myelotoxicity
torsade de pointes, myelotoxicity
torsade de pointes, myelotoxicity
myelotoxicity
torsade de pointes, myelotoxicity
torsade de pointes, myelotoxicity
torsade de pointes, myelotoxicityhigh
intermediate
high
high
high
intermediate
high
high
high
intermediate
high
high
high

intermediate

hypoglycemia

intermediate

saxagliptin

intermediate

hypoglycemiaintermediate

Anti-Infective Agents
albendazole
artemether
erythromycin
etravirine
halofantrine
maraviroc
praziquantel
primaquine
quinine

low
low
intermediate
not known
low
low
lowintermediate
intermediate

dizziness, headache, nausea
enhanced anti-malarial efficacy
torsade de pointes
skin rash
torsade de pointes
postural hypotension, syncope
dizziness, headache,somnolence
myelotoxicity
torsade de pointes

intermediate
low
high
low
very high
very high
intermediate
high
high

Anti-Cancer Agents
crizotinib
cyclophosphamide
dasatinib
erlotinibeverolimus
imatinib
lapatinib
nilotinib
pazopanib
sorafenib
sunitinib
vandetanib
venurafenib
Anti-Diabetic Agents
repaglinide

Potential Alternative
Medication(s)***

imatinib

imatinibsorafenib
sorafenib

glyburide, metformin,
sitagliptin
glyburide, metformin,
sitagliptin

clarithromycin
doxycycline
enfuvirtide
doxycycline
doxycycline

Appendix to: Bailey DG,...